SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):330P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Nanni, C.
Right arrow Articles by Fanti, S.
PubMed
Right arrow Articles by Nanni, C.
Right arrow Articles by Fanti, S.

Oncology-Basic Science: Therapy, Metrics & Intervention

Therapy, Metrics & Intervention Posters

In vivo molecular imaging of neuroblastoma (NB) progression by small animal PET in the TH-MYCN transgenic mouse model (TMM)

Cristina Nanni1, Carmelo Quarta1, Roberto Tonelli2, Erika Cantelli2, Korinne Di Leo2, Valentina Ambrosini1, Silvia Trespidi1, Domenico Rubello3, Andrea Pession2 and Stefano Fanti2

1 Nuclear Medicine, Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Italy; 2 Pediatric Hematology-Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy; 3 S. Maria della Misericrodia, Rovigo, Italy

1400

Objectives: The TMM in which expression of the MYCN oncogene is targeted to neural crest cells with the use of a tyrosine hydroxylase promoter (TH-MYCN) closely recapitulates human NB and is an in vivo model to evaluate new therapies in an immunocompetent context. The aim of the study was to evaluate the accuracy of 18F-FDG and 18F-DOPA PET to early detect NB in TH-MYCN mice and to evaluate the metabolic behavior during the tumor progression.

Methods: Homozygous and hemizygous TH-MYCN mice in the 129/SvJ background were used. For the PET, all the animals were evaluated with 18F-FDG and a subgroup was studied also with 18F-DOPA. Each animal underwent repeated PET scans. The animals were studied from the fourth week of age on, approximately once a week. The PET images were interpreted visually and semi-quantitatively (TBR). All the animals were sacrificed and histology was available to verify PET results.

Results: According to our results, FDG turned out to be more sensitive that F-DOPA for the early detection and progression evaluation of the tumour. FDG TBR was superior as well as the image quality. This was probably due to the very high malignancy of the tumour. Furthermore, the urinary excretion of F-DOPA turned out to be very high, saturating the images and reducing the diagnostic power of the technique.

Conclusions: FDG small animal PET is feasible to evaluate the TH-MYCN mouse model and can improve the accuracy of in vivo preclinical eventual testing of new therapies by ensuring that homogeneous conditions are applied in all the animals under study.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Nanni, C.
Right arrow Articles by Fanti, S.
PubMed
Right arrow Articles by Nanni, C.
Right arrow Articles by Fanti, S.